Details of the Drug

General Information of Drug (ID: DMQCTIH)

• Drug Name: Digoxin
• Synonyms: digoxin; 20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin

Indication

Disease Entry	ICD 11	Status	REF
Arrhythmia	BC9Z	Approved	[1]
Atrial fibrillation	BC81.3	Approved	[2]
Chronic heart failure	BD1Z	Approved	[2]
Congestive cardiac insufficiency	BD1Z	Approved	[1]
Heart failure	BD10-BD13	Approved	[1]

• Therapeutic Class: Antiarrhythmic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 780.9
  Logarithm of the Partition Coefficient (xlogp); 1.3
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 6
  Hydrogen Bond Acceptor Count (hbondacc); 14
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 1.32 +/- 0.18 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.0 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
  Bioavailability: The bioavailability of drug is 50-90% [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 1.7 mL/min/kg [5]
  Elimination: After intravenous (IV) administration to healthy subjects, 50-70% of the dose is measured excreted as unchanged digoxin in the urine [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 - 2 days (in healthy subjects) [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0000128 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.7% [5]
  Vd: The volume of distribution (Vd) of drug is 475-500 L [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.986 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Iron and trace metal metabolism disorders	Not Available	HMGCR	OTRT3F3U	[8]
Iron and trace metal metabolism disorders	Not Available	ATP1A1	OTCJ458Q	[8]
Mitochondrial toxicity	Not Available	CASP3	OTIJRBE7	[8]
Tumour necrosis	Not Available	HRAS	OTFYE6AJ	[8]

• Chemical Identifiers:
  Formula: C41H64O14
  IUPAC Name: 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
  Canonical SMILES: C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
  InChI: InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
  InChIKey: LTMHDMANZUZIPE-PUGKRICDSA-N
• Cross-matching ID:
  PubChem CID: 2724385
  ChEBI ID: CHEBI:4551
  CAS Number: 20830-75-5
  DrugBank ID: DB00390
  TTD ID: D02OZE
  VARIDT ID: DR00148
  INTEDE ID: DR0498
  ACDINA ID: D00198
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Organic anion transporter M1 (SLCO4C1)	TTACFNR	SO4C1_HUMAN	Modulator	[9]
Sodium/potassium-transporting ATPase (SPT ATPase)	TTQ38E9	AT1A1_HUMAN ; AT1A2_HUMAN ; AT1A3_HUMAN ; AT1B1_HUMAN ; AT1B2_HUMAN ; AT1B3_HUMAN	Inhibitor	[10]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance protein 3 (ABCB4)	DTZRMK5	MDR3_HUMAN	Substrate	[11]
Organic solute transporter subunit alpha (SLC51A)	DTMEQ32	OSTA_HUMAN	Substrate	[12]
Organic solute transporter subunit beta (SLC51B)	DT1V9AJ	OSTB_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 4C1 (SLCO4C1)	DTY0QMU	SO4C1_HUMAN	Substrate	[13]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[14]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[15]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[16]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[17]
Cardiac glycoside reductase 2 (cgr2)	DE9VSLW	CGR2_EGGLE	Substrate	[18]
Cardiac glycoside reductase 1 (cgr1)	DE84PFW	CGR1_EGGLE	Substrate	[18]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Drug Response	[8]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[19]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[20]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[21]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Gene/Protein Processing	[21]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Gene/Protein Processing	[21]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Drug Response	[8]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Gene/Protein Processing	[19]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Drug Response	[22]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Gene/Protein Processing	[21]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Digoxin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Furosemide	DMMQ8ZG	Moderate	Increased risk of hypokalemia by the combination of Digoxin and Furosemide.	Heart failure [BD10-BD1Z]	[23]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypokalemia by the combination of Digoxin and Bumetanide.	Heart failure [BD10-BD1Z]	[23]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[23]

Coadministration of a Drug Treating the Disease Different from Digoxin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Digoxin due to formation of complexes caused by Sodium bicarbonate.	Acidosis [5C73]	[24]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[25]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Digoxin due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[25]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[26]
Scopolamine	DMOM8AL	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Scopolamine.	Addictive disorder [6C50-6C5Z]	[27]
Framycetin	DMF8DNE	Minor	Altered absorption of Digoxin caused by Framycetin.	Alcoholic liver disease [DB94]	[28]
Paromomycin	DM1AGXN	Minor	Altered absorption of Digoxin caused by Paromomycin.	Amoebiasis [1A36]	[28]
Nifedipine	DMSVOZT	Moderate	Decreased renal excretion of Digoxin caused by Nifedipine.	Angina pectoris [BA40]	[29]
Clorazepate	DMC3JST	Moderate	Increased plasma concentration of Digoxin and Clorazepate due to competitive binding of plasma proteins.	Anxiety disorder [6B00-6B0Z]	[30]
Alprazolam	DMC7XDN	Moderate	Increased plasma concentration of Digoxin and Alprazolam due to competitive binding of plasma proteins.	Anxiety disorder [6B00-6B0Z]	[31]
Halazepam	DMPFWO6	Moderate	Increased plasma concentration of Digoxin and Halazepam due to competitive binding of plasma proteins.	Anxiety disorder [6B00-6B0Z]	[31]
Chlordiazepoxide	DMTN5XI	Moderate	Increased plasma concentration of Digoxin and Chlordiazepoxide due to competitive binding of plasma proteins.	Anxiety disorder [6B00-6B0Z]	[31]
Oxazepam	DMXNZM4	Moderate	Increased plasma concentration of Digoxin and Oxazepam due to competitive binding of plasma proteins.	Anxiety disorder [6B00-6B0Z]	[31]
Levalbuterol	DM5YBO1	Moderate	Interference of cell/tissue uptake of Digoxin by Levalbuterol.	Asthma [CA23]	[32]
Salbutamol	DMN9CWF	Moderate	Interference of cell/tissue uptake of Digoxin by Salbutamol.	Asthma [CA23]	[32]
Kanamycin	DM2DMPO	Minor	Altered absorption of Digoxin caused by Kanamycin.	Bacterial infection [1A00-1C4Z]	[28]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[33]
Oxytetracycline	DMOVH1M	Moderate	Altered absorption of Digoxin due to GI flora changes caused by Oxytetracycline.	Bacterial infection [1A00-1C4Z]	[34]
Troleandomycin	DMUZNIG	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[35]
Minocycline	DMVN5OH	Moderate	Altered absorption of Digoxin due to GI flora changes caused by Minocycline.	Bacterial infection [1A00-1C4Z]	[34]
Tetracycline	DMZA017	Moderate	Altered absorption of Digoxin due to GI flora changes caused by Tetracycline.	Bacterial infection [1A00-1C4Z]	[34]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[36]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[37]
Mannitol	DMSCDY9	Moderate	Increased risk of hypokalemia by the combination of Digoxin and Mannitol.	Bronchiectasis [CA24]	[23]
Demeclocycline	DMZEPFJ	Moderate	Altered absorption of Digoxin due to GI flora changes caused by Demeclocycline.	Bronchitis [CA20]	[34]
Atorvastatin	DMF28YC	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Atorvastatin.	Cardiovascular disease [BA00-BE2Z]	[38]
PF-04449913	DMSB068	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[25]
Ardeparin	DMYRX8B	Minor	Increased plasma concentration of Digoxin and Ardeparin due to competitive binding of plasma proteins.	Coronary thrombosis [BA43]	[39]
Mifepristone	DMGZQEF	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Mifepristone.	Cushing syndrome [5A70]	[40]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Digoxin and Pasireotide.	Cushing syndrome [5A70]	[41]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[42]
Hyoscyamine	DM804UR	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Hyoscyamine.	Digestive system disease [DE2Z]	[27]
Mepenzolate	DM8YU2F	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Mepenzolate.	Digestive system disease [DE2Z]	[27]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Digoxin due to formation of complexes caused by SODIUM CITRATE.	Discovery agent [N.A.]	[24]
Oxybutynine	DMJPBAX	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Oxybutynine.	Discovery agent [N.A.]	[27]
Diazepam	DM08E9O	Moderate	Increased plasma concentration of Digoxin and Diazepam due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[31]
Clonazepam	DMTO13J	Moderate	Increased plasma concentration of Digoxin and Clonazepam due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[31]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Digoxin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Ethacrynic acid.	Essential hypertension [BA00]	[43]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Bendroflumethiazide.	Essential hypertension [BA00]	[23]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Benzthiazide.	Essential hypertension [BA00]	[23]
Solifenacin	DMG592Q	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Solifenacin.	Functional bladder disorder [GC50]	[27]
Tolterodine	DMSHPW8	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Tolterodine.	Functional bladder disorder [GC50]	[27]
Darifenacin	DMWXLYZ	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Darifenacin.	Functional bladder disorder [GC50]	[27]
Itraconazole	DMCR1MV	Major	Decreased clearance of Digoxin due to the transporter inhibition by Itraconazole.	Fungal infection [1F29-1F2F]	[44]
Propantheline	DM2EN6G	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Propantheline.	Gastric ulcer [DA60]	[27]
Dexlansoprazole	DM1DBV5	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[33]
Acetazolamide	DM1AF5U	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Acetazolamide.	Glaucoma [9C61]	[23]
Methazolamide	DM7J2TA	Moderate	Increased risk of hypokalemia by the combination of Digoxin and Methazolamide.	Glaucoma [9C61]	[23]
Dichlorphenamide	DMH7IDQ	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Dichlorphenamide.	Glaucoma [9C61]	[43]
Colchicine	DM2POTE	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Colchicine.	Gout [FA25]	[45]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[46]
Procarbazine	DMIK367	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[47]
Etravirine	DMGV8QU	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Etravirine.	Human immunodeficiency virus disease [1C60-1C62]	[41]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[48]
Nisoldipine	DM7ISKJ	Moderate	Decreased renal excretion of Digoxin caused by Nisoldipine.	Hypertension [BA00-BA04]	[29]
Indapamide	DMGN1PW	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Indapamide.	Hypertension [BA00-BA04]	[23]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hypokalemia by the combination of Digoxin and Trichlormethiazide.	Hypertension [BA00-BA04]	[23]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[23]
Levothyroxine	DMHN027	Moderate	Increased renal excretion of Digoxin caused by Levothyroxine.	Hypo-thyroidism [5A00]	[49]
Belladonna	DM2RBWK	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Belladonna.	Infectious gastroenteritis/colitis [1A40]	[27]
Suvorexant	DM0E6S3	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Suvorexant.	Insomnia [7A00-7A0Z]	[50]
Flurazepam	DMAL4G0	Moderate	Increased plasma concentration of Digoxin and Flurazepam due to competitive binding of plasma proteins.	Insomnia [7A00-7A0Z]	[31]
Triazolam	DMETYK5	Moderate	Increased plasma concentration of Digoxin and Triazolam due to competitive binding of plasma proteins.	Insomnia [7A00-7A0Z]	[31]
Quazepam	DMY4D87	Moderate	Increased plasma concentration of Digoxin and Quazepam due to competitive binding of plasma proteins.	Insomnia [7A00-7A0Z]	[31]
Estazolam	DMZGXUM	Moderate	Increased plasma concentration of Digoxin and Estazolam due to competitive binding of plasma proteins.	Insomnia [7A00-7A0Z]	[31]
Clidinium	DMUMQZ0	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Clidinium.	Irritable bowel syndrome [DD91]	[27]
Dicyclomine	DMZSDGX	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Dicyclomine.	Irritable bowel syndrome [DD91]	[27]
Remimazolam	DMLVSYX	Moderate	Increased plasma concentration of Digoxin and Remimazolam due to competitive binding of plasma proteins.	Labour/delivery anaesthesia complication [JB0C]	[31]
Methotrexate	DM2TEOL	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Methotrexate.	Leukaemia [2A60-2B33]	[47]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[51]
Quinine	DMSWYF5	Moderate	Decreased elimination of Digoxin caused by Quinine mediated competitive inhibition of bile excretion.	Malaria [1F40-1F45]	[52]
Fludarabine	DMVRLT7	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[47]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[25]
Vincristine	DMINOX3	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Vincristine.	Mature B-cell lymphoma [2A85]	[47]
Cytarabine	DMZD5QR	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Cytarabine.	Mature B-cell lymphoma [2A85]	[47]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Digoxin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[41]
Midazolam	DMXOELT	Moderate	Increased plasma concentration of Digoxin and Midazolam due to competitive binding of plasma proteins.	Mood/affect symptom [MB24]	[31]
Carfilzomib	DM48K0X	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Carfilzomib.	Multiple myeloma [2A83]	[25]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Digoxin and Thalidomide.	Multiple myeloma [2A83]	[26]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Digoxin and Siponimod.	Multiple sclerosis [8A40]	[26]
Fingolimod	DM5JVAN	Major	Increased risk of bradycardia by the combination of Digoxin and Fingolimod.	Multiple sclerosis [8A40]	[53]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Digoxin and Ozanimod.	Multiple sclerosis [8A40]	[54]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[55]
Metoclopramide	DMFA5MY	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Metoclopramide.	Nausea/vomiting [MD90]	[56]
Metolazone	DMB39LO	Moderate	Increased risk of hypomagnesemia by the combination of Digoxin and Metolazone.	Oedema [MG29]	[23]
Polythiazide	DMCH80F	Moderate	Increased risk of hypokalemia by the combination of Digoxin and Polythiazide.	Oedema [MG29]	[23]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Digoxin caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[26]
Flavoxate	DMKV4NL	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Flavoxate.	Pain [MG30-MG3Z]	[27]
Biperiden	DME78OA	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Biperiden.	Parkinsonism [8A00]	[27]
Methylscopolamine	DM5VWOB	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Methylscopolamine.	Peptic ulcer [DA61]	[27]
Esomeprazole	DM7BN0X	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Esomeprazole.	Peptic ulcer [DA61]	[33]
Lonafarnib	DMGM2Z6	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[57]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Digoxin due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[58]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Digoxin and Amisulpride.	Schizophrenia [6A20]	[25]
Cyclophosphamide	DM4O2Z7	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Cyclophosphamide.	Solid tumour/cancer [2A00-2F9Z]	[47]
Vandetanib	DMRICNP	Moderate	Decreased clearance of Digoxin due to the transporter inhibition by Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[26]
Doxorubicin	DMVP5YE	Moderate	Decreased absorption of Digoxin due to intestinal mucosa variation caused by Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[47]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Digoxin caused by Pitolisant mediated induction of UGT.	Somnolence [MG42]	[25]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Digoxin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[59]
Albiglutide	DM1JEGF	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Albiglutide.	Type 2 diabetes mellitus [5A11]	[60]
Liraglutide	DM3FXPS	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Liraglutide.	Type 2 diabetes mellitus [5A11]	[61]
Atropine	DMEN6X7	Minor	Altered absorption of Digoxin due to GI dynamics variation caused by Atropine.	Unspecific substance harmful effect [NE6Z]	[27]
Amiodarone	DMUTEX3	Major	Increased plasma concentration of Digoxin and Amiodarone due to competitive binding of plasma proteins.	Ventricular tachyarrhythmia [BC71]	[62]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C green no. 5	E00265	20431	Colorant
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Digoxin 0.125 mg tablet	0.125 mg	Oral Tablet	Oral
Digoxin 0.25 mg tablet	0.25 mg	Oral Tablet	Oral
Digoxin 125 mcg tablet	125 mcg	Oral Tablet	Oral
Digoxin 0.0625 mg tablet	0.0625 mg	Oral Tablet	Oral
Digoxin 0.1875 mg tablet	0.1875 mg	Oral Tablet	Oral
Digoxin 250 mcg tablet	250 mcg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4726).
• [2] Digoxin FDA Label
• [3] Iisalo E: Clinical pharmacokinetics of digoxin. Clin Pharmacokinet. 1977 Jan-Feb;2(1):1-16. doi: 10.2165/00003088-197702010-00001.
• [4] BDDCS applied to over 900 drugs
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] FDA Approved Drug Products: Lanoxin (digoxin) oral tablets
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227).
• [10] Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33.
• [11] MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
• [12] Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
• [13] Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
• [14] Drug Interactions in Infectious Diseases.
• [15] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [16] MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12.
• [17] Omeprazole-associated digoxin toxicity. South Med J. 2007 Apr;100(4):400-2.
• [18] Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8.
• [19] Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1alpha in human colon cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):385-92. doi: 10.1016/j.taap.2009.07.026. Epub 2009 Jul 30.
• [20] Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 2005 Jan;312(1):144-52. doi: 10.1124/jpet.104.073916. Epub 2004 Sep 13.
• [21] Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
• [22] Insulin interacts directly with Na?/K?ATPase and protects from digoxin toxicity. Toxicology. 2012 Sep 4;299(1):1-9. doi: 10.1016/j.tox.2012.04.013. Epub 2012 May 4.
• [23] Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
• [24] Allen MD, Greenblatt DJ, Harmatz JS, Smith TW "Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules." J Clin Pharmacol 21 (1981): 26-30. [PMID: 7012189]
• [25] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [26] Cerner Multum, Inc. "Australian Product Information.".
• [27] Binnion PF, McDermott M, LeSher D "Bioavailability of digoxin." Lancet 1 (1973): 1118. [PMID: 4122032]
• [28] Lindenbaum J, Maulitz RM, Butler VP "Inhibition of digoxin absorption by neomycin." Gastroenterology 71 (1976): 399-404. [PMID: 950089]
• [29] Belz GG, Aust PE, Munkes R "Digoxin plasma concentrations and nifedipine ." Lancet 1 (1981): 844-5. [PMID: 6111709]
• [30] Ochs HR, Greenblatt DJ, Verburg-Ochs B "Effect of alprazolam on digoxin kinetics and creatinine clearance." Clin Pharmacol Ther 38 (1985): 595-8. [PMID: 2865030]
• [31] Castillo-Ferrando JR, Garcia M, Carmona J "Digoxin levels and diazepam." Lancet 2 (1980): 368. [PMID: 6105500]
• [32] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [33] Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
• [34] Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med 305 (1981): 789-94. [PMID: 7266632]
• [35] Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
• [36] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [37] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [38] Boyd RA, Stern RH, Stewart BH, et al. "Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion." J Clin Pharmacol 40 (2000): 91-8. [PMID: 10631627]
• [39] Storstein L, Janssen H "Studies on digitalis VI: the effect of heparin on serum protein binding of digitoxin and digoxin." Clin Pharmacol Ther 20 (1976): 15-23. [PMID: 1277722]
• [40] Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
• [41] Canadian Pharmacists Association.
• [42] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [43] Semple P, Tilstone WJ, Lawson DH "Furosemide and urinary digoxin clearance." N Engl J Med 293 (1975): 612-3. [PMID: 902451]
• [44] Alderman CP, Allcroft PD "Digoxin-itraconazole interaction: possible mechanisms." Ann Pharmacother 31 (1997): 438-40. [PMID: 9101006]
• [45] Product Information. Colcrys (colchicine). AR Scientific Inc, Philadelphia, PA.
• [46] Becquemont L, Verstuyft C, Kerb R, et al. "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther 70 (2001): 311-6. [PMID: 11673746]
• [47] Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R "Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations." Clin Pharmacol Ther 39 (1986): 25-8. [PMID: 3943266]
• [48] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [49] Frye RL, Braunwald E "Studies on digitalis. III: The influence of triiodothyronine on digitalis requirements." Circulation 23 (1961): 376-82. [PMID: 13702336]
• [50] Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
• [51] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [52] Brater DC, Morrelli HF "Systemic alkalosis and digitalis related arrhythmias." Acta Med Scand Suppl 647 (1981): 79-85. [PMID: 6942644]
• [53] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [54] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [55] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [56] Fraser EJ, Leach RH, Poston JW, Bold AM, Culank LS, Lipede AB "Dissolution-rates and bioavailability of digoxin tablets." Lancet 1 (1973): 1393. [PMID: 4122785]
• [57] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [58] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [59] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [60] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [61] Product Information. Victoza (liraglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
• [62] Bajaj BP, Baig MW, Perrins EJ "Amiodarone-induced torsades de pointes: the possible facilitatory role of digoxin." Int J Cardiol 33 (1991): 335-7. [PMID: 1743800]